Randomization and treatment
toxicity, PD, death, toxicities
DISEASE
An interactive web response system assigned treatment. Investigational treatments were administered orally with or without food on a 28‐day cycle, unless otherwise noted. Standard chemotherapy was administered according to prescribing label recommendations. Treatment was continued until progressive disease (PD), unacceptable toxicity, death, or withdrawal from the study.In the safety lead‐in, patients received abemaciclib continuously (150 mg twice daily [BID]) plus galunisertib (150 mg BID) for 14 days followed by a 14‐day rest period. In Stage 1, patients were randomized 1:1:1 to receive abemaciclib monotherapy (200 mg twice daily), abemaciclib (150 mg BID) plus LY3023414 (150 mg BID), or SOC chemotherapy of the physician's choice with gemcitabine (1000 mg/mDose modifications of investigational agents were allowed for treatment‐related toxicities and followed protocol guidance. Standard chemotherapy dose modifications followed on‐label recommendations.Patients received full supportive care during the study per institutional guidelines. The use of granulocyte‐colony stimulating factors and erythropoietin was permitted in accordance with American Society of Clinical Oncology/American Society of Hematology guidelines.